Navigation Links
Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, Study Shows
Date:11/12/2008

Largest randomized trial of its kind shows no clinically meaningful difference between contacts and glasses for progression of nearsightedness

JACKSONVILLE, Fla., Nov. 12 /PRNewswire/ -- Soft contact lens wear does not result in clinically significant acceleration in the development of nearsightedness in children and does not cause relevant increases in axial length or corneal curvature, a new study shows. Findings from the three-year study, the largest randomized trial of its kind, appear in the November issue of Investigative Ophthalmology & Visual Science, the official journal of The Association for Research in Vision and Ophthalmology.

According to the multi-site wearing trial study, which tracked the myopic progression of 484 children ages 8-11 randomly assigned to wear glasses or contact lenses, there is no clinically meaningful difference between the two forms of vision correction for the treatment of nearsightedness, a vision problem experienced by approximately one-third of the population.

The new research further dispels a long held myth that soft contact lenses increase myopia progression (a/k/a "Myopic Creep") in children more than other vision correction options.

"Children as young as eight years old who require vision correction are capable of contact lens wear and this study confirms that they can safely be fit in soft contact lenses to correct their myopia," says Jeffrey J. Walline, O.D., Ph.D., Ohio State University College of Optometry and leader of the Adolescent and Child Health Initiative to Encourage Vision Empowerment (ACHIEVE) Study, of which this research was a part.

"Recent clinical studies have demonstrated that contact lenses provide a number of quality of life benefits to children beyond simply correcting their myopia," he adds. "The combined body of research should give both doctors and parents greater confidence in presenting children with the option of contact lens wear when vision correction is required."

Myopia affects approximately 15 percent of children in the United States, but is much higher in some other countries such as Singapore and China. It typically develops around 8 years of age and worsens until age 15 or 16. A nearsighted child has difficulty seeing objects clearly at a distance, like a blackboard, but can see clearly up-close, such as when reading a book. Myopia can be corrected with glasses, contact lenses and refractive eye surgery.

Doctors will typically evaluate a child's maturity and level of parental support in deciding whether the child is ready for contact lenses.

About the Study

The purpose of this part of the ACHIEVE study was to measure the refractive error, corneal curvature, and axial length of eight to 11 year old children randomly assigned to wear single vision glasses or soft contact lenses (1-DAY ACUVUE(R) Brand Contact Lenses or ACUVUE(R) 2 Brand Contact Lenses, VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc.) for three years to compare the rate of myopic progression with each mode of correction over three years.

A total of 484 eight- to 11-year old myopic children participated in the randomized, single-masked, trial conducted from September 2003 to October 2007 at five clinical centers in the United States. Children were randomly assigned to wear spectacles (n = 237) or contact lenses (n = 247) for three years.

Among those who were assigned to wear contact lenses, 93.3 percent elected to wear 1-DAY ACUVUE(R) Brand Contact Lenses, a single use lens, rather than the other two-week modality. At the conclusion of the study, nine in ten children (90.7 percent) originally assigned to wear contact lenses at the first visit were still wearing contact lenses.

Measurements were conducted prior to randomization and annually. Nearly all (467 - 96.5%) of the subjects were examined at the final visit. The spectacle wearers progressed -1.08 +/- 0.71 D, and the contact lens wearers progressed -1.27 +/- 0.72 D (analysis of covariance, p = 0.005); although this difference is statistically significant, the difference is less than can be clinically measured. The axial growth of the spectacle wearers was 0.59 +/- 0.37 mm and 0.63 +/- 0.34 mm for the contact lens wearers (analysis of covariance, p = 0.27). The change in the steep corneal meridian was 0.05 +/- 0.69 D for the spectacle wearers and 0.10 +/- 0.70 D for the contact lens wearers (analysis of covariance, p = 0.43). These differences were not statistically significant.

The study was supported by funding from VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc.

ACUVUE(R), Brand Contact Lenses are indicated for vision correction. As with any contact lenses, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc., by calling 1-800-843-2020 or by visiting http://www.jnjvisioncare.com (for eye care professionals) or http://www.acuvue.com (for consumers).

ACUVUE(R), ACUVUE(R) 2, 1-DAY ACUVUE(R) and VISTAKON(R) are trademarks of Johnson & Johnson Vision Care, Inc.


'/>"/>
SOURCE VISTAKON, Division of Johnson & Johnson Vision Care, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers
2. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
3. Study Says Allergy Shots Help Children, Reduce Health Care Costs
4. New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
5. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
11. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health ... annual Analyst Day in New York City on Thursday, December 15, 2016, ... Health leadership team will provide an in-depth review of ... shareholder value. The company will also discuss 2017 earnings ... video webcast of the event will be broadcast simultaneously ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- Around the corners of world, cancer has infused ... present over earth. Cancer has become one of those ... time this is because of the increasing incidence rates ... steady increase in global cancer incidence with its associated ... of treatment, there is increasing interest in this stringent ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The ... how this current generation fits into Bible Prophecy. Yisrayl says this generation, known as ... to this conclusion, showing how the details line up exactly with Bible Prophecy – ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... ... and pharmaceutical organizations to build intelligent, connected applications, was named the best Sales ... , The winner announcement was made today by the Software & Information ...
Breaking Medicine News(10 mins):